Your browser is no longer supported. Please, upgrade your browser.
Settings
CDAK [NASD]
Codiak BioSciences, Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own2.80% Shs Outstand19.72M Perf Week-10.53%
Market Cap524.55M Forward P/E- EPS next Y-4.52 Insider Trans0.00% Shs Float16.67M Perf Month41.11%
Income-95.40M PEG- EPS next Q-1.54 Inst Own20.90% Short Float4.21% Perf Quarter172.82%
Sales1.40M P/S374.68 EPS this Y-75.00% Inst Trans- Short Ratio2.94 Perf Half Y-
Book/sh- P/B- EPS next Y75.70% ROA- Target Price35.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.90 - 37.85 Perf YTD-17.65%
Dividend- P/FCF- EPS past 5Y- ROI43.80% 52W High-29.72% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low236.71% ATR3.49
Employees101 Current Ratio1.50 Sales Q/Q900.00% Oper. Margin- RSI (14)54.13 Volatility12.26% 16.15%
OptionableNo Debt/Eq- EPS Q/Q8.70% Profit Margin- Rel Volume0.44 Prev Close25.87
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume238.68K Price26.60
Recom1.50 SMA20-1.98% SMA5044.24% SMA20064.33% Volume104,273 Change2.82%
Nov-09-20Initiated Wedbush Outperform $19
Nov-09-20Initiated Goldman Buy $29
Jan-21-21 09:00AM  
Jan-13-21 11:58PM  
Dec-30-20 07:00AM  
Dec-21-20 09:00AM  
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-19-20 04:05PM  
Nov-09-20 08:00AM  
Oct-23-20 06:00PM  
Oct-13-20 07:04PM  
Codiak BioSciences, Inc. is harnessing exosomesAnatural intercellular messengersAto pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
VIR Vir Biotechnology, Inc. daily Stock Chart
VIR [NASD]
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-6.40 Insider Own0.30% Shs Outstand125.81M Perf Week11.07%
Market Cap4.79B Forward P/E- EPS next Y-2.43 Insider Trans-38.02% Shs Float109.35M Perf Month30.95%
Income-256.80M PEG- EPS next Q-0.71 Inst Own79.60% Short Float12.23% Perf Quarter17.24%
Sales75.60M P/S63.40 EPS this Y-443.30% Inst Trans0.10% Short Ratio12.97 Perf Half Y-17.44%
Book/sh6.46 P/B6.27 EPS next Y-2.50% ROA-39.40% Target Price54.86 Perf Year138.69%
Cash/sh6.99 P/C5.80 EPS next 5Y8.50% ROE-47.10% 52W Range16.09 - 75.00 Perf YTD51.34%
Dividend- P/FCF- EPS past 5Y- ROI-41.90% 52W High-45.96% Beta-
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low151.90% ATR2.86
Employees297 Current Ratio11.00 Sales Q/Q35.70% Oper. Margin- RSI (14)66.72 Volatility9.27% 8.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-52.30% Profit Margin- Rel Volume1.03 Prev Close42.40
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume1.03M Price40.53
Recom2.40 SMA2027.41% SMA5032.81% SMA20011.67% Volume1,057,857 Change-4.41%
Jan-20-21Reiterated H.C. Wainwright Buy $100 → $125
Oct-05-20Initiated BofA Securities Buy $55
Sep-14-20Upgrade Goldman Neutral → Buy $48 → $54
Sep-11-20Upgrade JP Morgan Underweight → Neutral $29
Aug-20-20Initiated Needham Buy $62
Mar-19-20Downgrade JP Morgan Neutral → Underweight $26
Mar-13-20Downgrade Goldman Buy → Neutral
Feb-27-20Downgrade Robert W. Baird Neutral → Underperform $17
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Jan-20-21 01:43PM  
Jan-13-21 02:11PM  
10:00AM  
Jan-12-21 04:31PM  
03:26PM  
08:00AM  
03:00AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Dec-22-20 11:00AM  
Dec-18-20 09:12AM  
07:45AM  
Dec-17-20 04:01PM  
Dec-10-20 08:00AM  
Dec-08-20 01:09PM  
Dec-04-20 10:11AM  
Dec-02-20 03:51PM  
Nov-24-20 09:47AM  
Nov-16-20 02:55AM  
Nov-13-20 09:08AM  
Nov-10-20 04:01PM  
Nov-06-20 08:00AM  
Oct-27-20 04:01PM  
Oct-21-20 08:00AM  
Oct-13-20 04:01PM  
11:26AM  
Oct-12-20 09:31AM  
Oct-09-20 08:00AM  
Oct-07-20 01:44PM  
01:01PM  
08:47AM  
07:24AM  
Oct-06-20 04:25PM  
11:28AM  
10:46AM  
10:03AM  
09:49AM  
08:18AM  
Sep-29-20 06:08PM  
Sep-26-20 06:16AM  
Sep-24-20 08:00AM  
Sep-23-20 12:41PM  
Sep-22-20 10:01AM  
09:43AM  
Sep-15-20 06:30AM  
Sep-09-20 04:10PM  
Sep-08-20 04:01PM  
Sep-02-20 07:25AM  
Sep-01-20 04:01PM  
09:39AM  
09:09AM  
Aug-31-20 03:39PM  
03:17PM  
12:45PM  
08:50AM  
08:00AM  
Aug-20-20 09:51AM  
08:00AM  
Aug-11-20 04:01PM  
06:40AM  
Jul-28-20 04:01PM  
Jul-10-20 04:02PM  
04:01PM  
Jul-07-20 10:25PM  
05:58PM  
Jul-06-20 07:00AM  
Jun-08-20 02:06PM  
Jun-05-20 01:22PM  
Jun-04-20 03:57PM  
Jun-02-20 08:00AM  
Jun-01-20 12:23PM  
11:00AM  
May-29-20 08:00AM  
May-27-20 08:00AM  
May-23-20 08:13AM  
May-19-20 09:31AM  
May-18-20 05:28PM  
05:00PM  
02:47PM  
05:05AM  
May-15-20 03:09PM  
01:03PM  
May-12-20 04:01PM  
May-08-20 04:01PM  
May-07-20 04:01PM  
May-05-20 03:26PM  
03:11PM  
May-04-20 10:23AM  
08:24AM  
07:30AM  
Apr-28-20 08:00AM  
Apr-16-20 08:09AM  
Apr-15-20 04:01PM  
Apr-08-20 10:05AM  
07:00AM  
Apr-07-20 11:00AM  
Apr-06-20 04:03PM  
09:56AM  
08:12AM  
08:01AM  
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Virgin HerbertEVP, Research & CSOJan 15Option Exercise1.5310,53016,11143,730Jan 19 05:00 PM
Virgin HerbertEVP, Research & CSOJan 15Sale38.0010,530400,14033,200Jan 19 05:00 PM
Virgin HerbertEVP, Research & CSOJan 12Option Exercise1.533,8055,82237,005Jan 13 06:38 PM
Virgin HerbertEVP, Research & CSOJan 12Sale29.363,805111,69633,200Jan 13 06:38 PM
Parrish JayChief Business OfficerJan 04Option Exercise1.496,94510,313229,167Jan 05 04:40 PM
Parrish JayChief Business OfficerJan 04Sale26.326,945182,795222,222Jan 05 04:40 PM
Virgin HerbertEVP, Research & CSODec 24Option Exercise1.539,50014,53533,200Dec 28 06:39 PM
Virgin HerbertEVP, Research & CSODec 22Option Exercise1.533,8055,82227,505Dec 23 06:06 PM
Virgin HerbertEVP, Research & CSODec 22Sale31.193,805118,68323,700Dec 23 06:06 PM
Virgin HerbertEVP, Research & CSODec 08Option Exercise1.533,8055,82227,505Dec 10 05:00 PM
Virgin HerbertEVP, Research & CSODec 08Sale31.273,805118,96623,700Dec 10 05:00 PM
Parrish JayChief Business OfficerDec 01Option Exercise1.526,94510,522229,167Dec 02 05:48 PM
Parrish JayChief Business OfficerDec 01Sale31.536,945218,968222,222Dec 02 05:48 PM
Virgin HerbertEVP, Research & CSONov 27Option Exercise1.532,9304,48326,630Dec 01 07:02 PM
Pang PhillipChief Medical OfficerNov 27Option Exercise0.867,5006,41357,277Dec 01 07:03 PM
Virgin HerbertEVP, Research & CSONov 27Sale30.002,93087,90023,700Dec 01 07:02 PM
Virgin HerbertEVP, Research & CSONov 24Option Exercise1.532,3403,58026,040Nov 25 05:00 PM
Virgin HerbertEVP, Research & CSONov 24Sale27.292,34063,84823,700Nov 25 05:00 PM
Pang PhillipChief Medical OfficerNov 12Option Exercise0.8620,00017,10049,777Nov 16 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Option Exercise1.532,3403,58026,040Nov 12 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Sale26.262,34061,44823,700Nov 12 05:00 PM
Pang PhillipChief Medical OfficerNov 04Option Exercise1.535,0007,65034,777Nov 05 05:00 PM
Parrish JayChief Business OfficerNov 02Option Exercise1.526,94410,520229,166Nov 03 05:00 PM
Parrish JayChief Business OfficerNov 02Sale31.276,944217,153222,222Nov 03 05:00 PM
Virgin HerbertEVP, Research & CSOOct 27Option Exercise1.533,8055,82227,505Oct 28 07:43 PM
Virgin HerbertEVP, Research & CSOOct 27Sale35.043,805133,33523,700Oct 28 07:43 PM
Pang PhillipChief Medical OfficerOct 21Option Exercise2.2112,50027,66742,277Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale35.4912,500443,60829,777Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale31.445,000157,20929,777Nov 05 05:00 PM
Virgin HerbertEVP, Research & CSOOct 13Option Exercise1.535,5608,50729,260Oct 14 06:33 PM
Virgin HerbertEVP, Research & CSOOct 13Sale43.035,560239,23623,700Oct 14 06:33 PM
Pang PhillipChief Medical OfficerOct 07Option Exercise1.5412,50019,22942,277Oct 08 05:00 PM
Pang PhillipChief Medical OfficerOct 07Sale41.7412,500521,79529,777Oct 08 05:00 PM
Parrish JayChief Business OfficerOct 01Option Exercise1.526,94510,522229,167Oct 02 05:19 PM
Parrish JayChief Business OfficerOct 01Sale34.756,945241,342222,222Oct 02 05:19 PM
Virgin HerbertEVP, Research & CSOSep 29Option Exercise1.533,5105,37027,210Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 29Sale38.003,510133,38023,700Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 24Option Exercise1.533,7005,66123,700Sep 28 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Option Exercise1.533,8055,82223,805Sep 23 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Sale31.713,805120,63820,000Sep 23 05:00 PM
Pang PhillipChief Medical OfficerSep 16Option Exercise2.2412,50028,00142,277Sep 18 05:00 PM
Pang PhillipChief Medical OfficerSep 16Sale31.9012,500398,69429,777Sep 18 05:00 PM
Virgin HerbertEVP, Research & CSOSep 08Option Exercise1.533,8055,82223,805Sep 10 04:30 PM
Virgin HerbertEVP, Research & CSOSep 08Sale29.993,805114,09820,000Sep 10 04:30 PM
Pang PhillipChief Medical OfficerSep 02Option Exercise1.5812,50019,68842,277Sep 03 04:23 PM
Pang PhillipChief Medical OfficerSep 02Sale32.8912,500411,15929,777Sep 03 04:23 PM
Parrish JayChief Business OfficerSep 01Option Exercise1.586,94310,935229,165Sep 03 04:22 PM
Parrish JayChief Business OfficerSep 01Sale39.156,943271,796222,222Sep 03 04:22 PM
Virgin HerbertEVP, Research & CSOAug 25Option Exercise1.5325,56039,10725,560Sep 10 04:29 PM
Virgin HerbertEVP, Research & CSOAug 25Sale42.925,560238,63220,000Sep 10 04:29 PM
Pang PhillipChief Medical OfficerAug 19Option Exercise1.5126,50039,99242,277Aug 21 04:39 PM
Pang PhillipChief Medical OfficerAug 19Sale50.9512,500636,85529,777Aug 21 04:39 PM
Virgin HerbertEVP, Research & CSOAug 11Option Exercise1.537,90012,0877,900Aug 12 04:30 PM
Virgin HerbertEVP, Research & CSOAug 11Sale51.087,900403,5630Aug 12 04:30 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:40 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:40 PM
Parrish JayChief Business OfficerAug 03Option Exercise1.5011,11016,665233,332Aug 04 05:14 PM
Parrish JayChief Business OfficerAug 03Sale47.6511,110529,404222,222Aug 04 05:14 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:28 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:03 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:03 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:28 PM
Pang PhillipChief Medical OfficerJul 15Option Exercise2.2412,50028,01828,277Jul 16 05:00 PM
Pang PhillipChief Medical OfficerJul 15Sale49.5312,500619,11815,777Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Option Exercise1.537,90012,0877,900Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Sale48.857,900385,8760Jul 16 05:00 PM
Horn HowardCFOJul 13Sale50.0630,0001,501,731177,777Jul 15 04:50 PM
Horn HowardCFOJul 02Sale40.0010,000400,000207,777Jul 02 06:42 PM
Pang PhillipChief Medical OfficerJul 01Option Exercise4.3712,50054,68728,277Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Option Exercise1.5475,000115,792297,222Jul 02 06:43 PM
Horn HowardCFOJul 01Sale37.8410,000378,399217,777Jul 02 06:42 PM
Pang PhillipChief Medical OfficerJul 01Sale37.7812,500472,25215,777Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Sale37.9575,0002,846,310222,222Jul 02 06:43 PM
Horn HowardCFOJun 25Sale50.0030,0001,500,000227,777Jun 26 05:00 PM
Virgin HerbertEVP, Research & CSOJun 24Option Exercise1.539,36014,3219,360Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 24Sale48.009,360449,2800Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Option Exercise1.535,5608,5075,560Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Sale38.995,560216,7780Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 19Option Exercise1.533,5105,3703,510Jun 23 05:00 PM
Virgin HerbertEVP, Research & CSOJun 19Sale38.003,510133,3840Jun 23 05:00 PM
Horn HowardCFOJun 19Sale40.0010,000400,000257,777Jun 23 05:00 PM
Pang PhillipChief Medical OfficerJun 17Option Exercise5.1812,50064,68828,277Jun 18 05:00 PM
Pang PhillipChief Medical OfficerJun 17Sale37.2712,500465,81515,777Jun 18 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Option Exercise1.533,8055,8223,805Jun 11 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Sale36.283,805138,0300Jun 11 05:00 PM
Pang PhillipChief Medical OfficerJun 03Option Exercise5.1812,50064,68828,277Jun 04 04:53 PM
Pang PhillipChief Medical OfficerJun 03Sale35.0712,500438,38715,777Jun 04 04:53 PM
Parrish JayChief Business OfficerJun 01Option Exercise1.4975,000111,375297,222Jun 02 09:15 PM
Parrish JayChief Business OfficerJun 01Sale35.2275,0002,641,410222,222Jun 02 09:15 PM
Horn HowardCFOJun 01Sale35.1010,000351,038267,777Jun 02 09:14 PM
Virgin HerbertEVP, Research & CSOMay 26Option Exercise1.533,8055,8223,805May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 26Sale34.083,805129,6740May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 18Option Exercise1.531,7552,6851,755May 19 05:21 PM
Virgin HerbertEVP, Research & CSOMay 18Sale38.001,75566,6900May 19 05:21 PM
Parrish JayChief Business OfficerMay 14Option Exercise1.4975,000111,375297,222May 15 07:18 PM
Virgin HerbertEVP, Research & CSOMay 14Option Exercise1.533,8055,8223,805May 15 07:48 PM
Virgin HerbertEVP, Research & CSOMay 14Sale30.073,805114,4180May 15 07:48 PM
Parrish JayChief Business OfficerMay 14Sale30.0575,0002,253,885222,222May 15 07:18 PM